Perspectives/NNS
of/IN
Integrative/JJ
Cancer/NN
Genomics/NNS
in/IN
Next/RB
Generation/NN
Sequencing/NN
Era/NN
./.
====================
The/DT
explosive/JJ
development/NN
of/IN
genomics/NNS
technologies/NNS
including/VBG
microarrays/NNS
and/CC
next/RB
generation/NN
sequencing/NN
(/(
NGS/NN
)/)
has/VBZ
provided/VBN
comprehensive/JJ
maps/VBZ
of/IN
cancer/NN
genomes/NNS
,/,
including/VBG
the/DT
expression/NN
of/IN
mRNAs/NNS
and/CC
microRNAs/NNS
,/,
DNA/NN
copy/NN
numbers/NNS
,/,
sequence/NN
variations/NNS
,/,
and/CC
epigenetic/JJ
changes/NNS
./.
====================
These/DT
genome-wide/NN
profiles/NNS
of/IN
the/DT
genetic/JJ
aberrations/NNS
could/MD
reveal/VB
the/DT
candidates/NNS
for/IN
diagnostic/JJ
and/or/CC
prognostic/JJ
biomarkers/NNS
as/IN
well/RB
as/IN
mechanistic/JJ
insights/NNS
into/IN
tumor/NN
development/NN
and/CC
progression/NN
./.
====================
Recent/JJ
efforts/NNS
to/TO
establish/VB
the/DT
huge/JJ
cancer/NN
genome/NN
compendium/NN
and/CC
integrative/JJ
omics/NNS
analyses/NNS
,/,
so-called/JJ
``/CD
integromics/NNS
''/CD
,/,
have/VBP
extended/VBN
our/PRP$
understanding/NN
on/IN
the/DT
cancer/NN
genome/NN
,/,
showing/VBG
its/PRP$
daunting/NN
complexity/NN
and/CC
heterogeneity/NN
./.
====================
However/RB
,/,
the/DT
challenges/NNS
of/IN
the/DT
structured/JJ
integration/NN
,/,
sharing/VBG
,/,
and/CC
interpretation/NN
of/IN
the/DT
big/NN
omics/NNS
data/NNS
still/RB
remain/VBP
to/TO
be/VB
resolved/VBN
./.
====================
Here/RB
,/,
we/PRP
review/VBP
several/JJ
issues/NNS
raised/VBD
in/IN
cancer/NN
omics/NNS
data/NNS
analysis/NN
,/,
including/VBG
NGS/NN
,/,
focusing/VBG
particularly/RB
on/IN
the/DT
study/NN
design/NN
and/CC
analysis/NN
strategies/NNS
./.
====================
This/DT
might/MD
be/VB
helpful/JJ
to/TO
understand/VB
the/DT
current/JJ
trends/NNS
and/CC
strategies/NNS
of/IN
the/DT
rapidly/RB
evolving/VBG
cancer/NN
genomics/NNS
research/NN
./.
====================
In/IN
the/DT
last/JJ
decade/NN
,/,
numerous/JJ
genomic/JJ
studies/NNS
have/VBP
addressed/VBN
the/DT
enormous/JJ
complexity/NN
of/IN
the/DT
cancer/NN
genome/NN
./.
====================
Genomic/JJ
profiling/VBG
using/VBG
microarray/NN
technology/NN
could/MD
stratify/VB
the/DT
tumors/NNS
into/IN
homogeneous/JJ
subgroups/NNS
,/,
providing/VBG
novel/JJ
clinical/JJ
insights/NNS
for/IN
the/DT
development/NN
of/IN
diagnostics/NNS
and/CC
therapeutics/NNS
as/IN
well/RB
as/IN
systematic/JJ
views/VBZ
on/IN
the/DT
underlying/VBG
mechanisms/NNS
of/IN
tumor/NN
progression/NN
./.
====================
In/IN
addition/NN
to/TO
the/DT
microarray/NN
technologies/NNS
,/,
explosive/JJ
advances/NNS
on/IN
sequencing/NN
technologies/NNS
have/VBP
been/VBN
made/VBN
recently/RB
,/,
which/WDT
is/VBZ
called/VBN
``/NN
next/RB
generation/NN
sequencing/NN
(/(
NGS/NN
)/)
./.
''/CD
====================
Compared/VBN
to/TO
the/DT
previous/JJ
DNA/NN
sequencing/NN
of/IN
the/DT
Sanger/NN
method/NN
using/VBG
dideoxynucleotide/JJ
termination/NN
reaction/NN
termed/VBN
as/IN
``/RB
first-generation/JJ
''/NNP
sequencing/NN
,/,
NGS/NN
uses/VBZ
massively/RB
parallel/JJ
sequencing/NN
method/NN
generating/VBG
hundreds/VBZ
of/IN
millions/NNS
of/IN
short/JJ
(/(
~200/CD
bp/NN
)/)
DNA/NN
reads/VBZ
,/,
which/WDT
can/MD
sequence/VB
a/DT
human/JJ
genome/NN
rapidly/RB
with/IN
extremely/RB
lower/JJR
cost/RB
./.
====================
The/DT
earlier/RBR
NGS/NN
method/NN
with/IN
the/DT
single-end/JJ
read/VBN
sequencing/NN
inevitably/RB
produces/VBZ
the/DT
short-read/JJ
problems/NNS
,/,
limiting/VBG
the/DT
accuracy/NN
of/IN
genome/NN
alignment/NN
./.
====================
This/DT
could/MD
be/VB
improved/VBN
by/IN
applying/VBG
a/DT
paired-end/NN
sequencing/NN
method/NN
,/,
allowing/VBG
substantial/JJ
advances/NNS
in/IN
identifying/VBG
not/RB
only/RB
point/NN
mutations/NNS
but/CC
also/RB
genomic/JJ
rearrangements/NNS
,/,
such/JJ
as/IN
deletions/NNS
,/,
amplifications/NNS
,/,
inversions/NNS
,/,
translocations/NNS
,/,
and/CC
gene-fusions/NNS
[/(
1/CD
,/,
2/CD
]/)
./.
====================
The/DT
NGS/NN
technology/NN
is/VBZ
now/RB
divided/VBN
into/IN
``/NN
second/JJ
generation/NN
sequencing/NN
''/CD
and/CC
``/NN
third/JJ
generation/NN
sequencing/NN
./.
''/CD
====================
The/DT
second/JJ
generation/NN
sequencing/NN
refers/VBZ
to/TO
the/DT
strategies/NNS
of/IN
short-read/JJ
alignment/NN
,/,
while/IN
the/DT
rapidly/RB
being/VBG
developed/VBN
technology/NN
of/IN
the/DT
third/JJ
generation/NN
sequencing/NN
refers/VBZ
to/TO
the/DT
single/JJ
DNA/NN
molecule/NN
based/VBN
sequencing/NN
./.
====================
The/DT
third/JJ
generation/NN
method/NN
has/VBZ
advantage/NN
of/IN
less/RBR
amount/NN
of/IN
DNA/NN
input/NN
that/DT
allows/VBZ
the/DT
emerging/VBG
field/NN
of/IN
single/JJ
cell/NN
sequencing/NN
[/(
3/CD
]/)
./.
====================
Moreover/RB
,/,
there/EX
is/VBZ
no/DT
step/NN
for/IN
PCR/NN
amplification/NN
,/,
therefore/RB
,/,
the/DT
nucleotide/NN
incorporation/NN
errors/NNS
can/MD
be/VB
handled/VBN
./.
====================
However/RB
,/,
all/DT
the/DT
platforms/NNS
of/IN
NGS/NN
technologies/NNS
still/RB
have/VBP
limitations/NNS
in/IN
accurate/JJ
base/NN
calling/JJ
and/CC
alignment/NN
./.
====================
The/DT
errors/NNS
are/VBP
likely/JJ
to/TO
be/VB
platform-dependent/JJ
,/,
which/WDT
increases/VBZ
the/DT
complexity/NN
of/IN
the/DT
data/NNS
analysis/NN
./.
====================
Therefore/RB
,/,
the/DT
cost/JJ
for/IN
bioinformatic/JJ
analysis/NN
,/,
rather/RB
than/IN
the/DT
sequencing/NN
itself/PRP
continues/VBZ
to/TO
grow/VB
,/,
which/WDT
is/VBZ
referred/VBN
to/TO
as/IN
``/RB
the/DT
$/NN
1,000/CD
genomes/NNS
,/,
the/DT
$/NN
100,000/CD
analysis/NN
''/RB
problem/NN
[/(
4/CD
]/)
./.
====================
The/DT
application/NN
of/IN
Exome-Seq/NN
and/CC
Whole/NN
Genome-Seq/NN
profiled/VBD
a/DT
mutational/JJ
spectrum/NN
in/IN
various/JJ
cancers/NNS
[/(
5-8/CD
]/)
./.
====================
The/DT
RNA-Seq/JJ
could/MD
profile/VB
not/RB
only/RB
the/DT
gene/NN
expressions/NNS
but/CC
also/RB
new/JJ
parameters/NNS
such/JJ
as/IN
allelic/JJ
expression/NN
,/,
alternative/JJ
splicing/NN
[/(
9/CD
,/,
10/CD
]/)
,/,
RNA-editing/JJ
[/(
11/CD
]/)
,/,
and/CC
alternative/JJ
polyadenylation/NN
of/IN
3'-untranaslated/JJ
region/NN
(/(
3'-UTR/NN
)/)
[/(
12/CD
,/,
13/CD
]/)
./.
====================
Structural/JJ
variations/NNS
such/JJ
as/IN
gene-fusions/NNS
,/,
e.g./FW
,/,
TMPRSS2-ERG/NN
in/IN
prostate/NN
cancer/NN
[/(
14/CD
]/)
and/CC
KIF5B-RET/NN
in/IN
lung/NN
cancer/NN
[/(
15/CD
]/)
have/VBP
been/VBN
identified/VBN
from/IN
the/DT
analysis/NN
of/IN
NGS/NN
data/NNS
./.
====================
Moreover/RB
,/,
the/DT
patterns/NNS
of/IN
genome/NN
rearrangements/NNS
can/MD
be/VB
analyzed/VBN
systematically/RB
./.
====================
For/IN
example/NN
,/,
a/DT
novel/JJ
pattern/NN
of/IN
genomic/JJ
rearrangement/NN
such/JJ
as/IN
fold-back/VBN
inversion/NN
could/MD
be/VB
found/VBN
by/IN
simply/RB
examining/VBG
the/DT
short/JJ
read/VBN
alignment/NN
of/IN
NGS/NN
data/NNS
[/(
16/CD
]/)
./.
====================
A/DT
novel/JJ
mechanism/NN
of/IN
cancer/NN
genome/NN
rearrangement/NN
i.e./FW
,/,
chromothripsis/NN
has/VBZ
been/VBN
proposed/VBN
,/,
which/WDT
represent/VBP
a/DT
catastrophic/JJ
event/NN
of/IN
fragmentation/NN
and/CC
reassembly/RB
of/IN
a/DT
single/JJ
chromosome/NN
[/(
17/CD
]/)
./.
====================
In/IN
addition/NN
,/,
high-resolution/JJ
epigenomic/JJ
profiles/NNS
of/IN
cancer/NN
genome/NN
could/MD
be/VB
obtained/VBN
by/IN
applying/VBG
NGS/NN
to/TO
chromatin/NN
immunoprecipitation-sequencing/VBG
(/(
ChIP-Seq/NN
)/)
and/CC
methylated/VBN
DNA/NN
immunoprecipitation-sequencing/NN
(/(
MeDIP-Seq/NNP
)/)
./.
====================
For/IN
example/NN
,/,
a/DT
recent/JJ
study/NN
of/IN
the/DT
genome-wide/NN
DNA/NN
methylation/NN
profile/NN
showed/VBD
novel/JJ
patterns/NNS
in/IN
which/WDT
the/DT
majority/NN
of/IN
DNA/NN
methylation/NN
changes/NNS
occurs/VBZ
at/IN
CpG/NN
island/NN
shores/VBZ
neighboring/JJ
the/DT
regions/NNS
up/IN
to/TO
2/CD
Kb/NN
from/IN
CpG/NN
islands/VBZ
,/,
and/CC
revealed/VBD
the/DT
patterns/NNS
of/IN
cancer-specific/JJ
and/CC
tissue-specific/JJ
DNA/NN
methylation/NN
[/(
18/CD
,/,
19/CD
]/)
./.
====================
Aberrant/JJ
histone/NN
modification/NN
was/VBD
also/RB
found/VBD
in/IN
cancers/NNS
showing/VBG
an/DT
association/NN
with/IN
the/DT
patient/NN
's/POS
prognosis/NN
[/(
20/CD
]/)
./.
====================
These/DT
studies/NNS
support/VBP
the/DT
pivotal/JJ
role/NN
of/IN
epigenetic/JJ
regulation/NN
in/IN
cancer/NN
development/NN
and/CC
progression/NN
./.
====================
Moving/VBG
forward/IN
,/,
new/JJ
applications/NNS
such/JJ
as/IN
genome-wide/JJ
translocation/NN
sequencing/NN
(/(
HTGTS/NNS
)/)
[/(
21/CD
]/)
and/CC
translocation/NN
capture/NN
sequencing/NN
(/(
TC-Seq/NN
)/)
[/(
22/CD
]/)
have/VBP
recently/RB
been/VBN
proposed/VBN
,/,
which/WDT
could/MD
profile/VB
the/DT
genome-wide/NN
translocation/NN
hotspots.Notably/RB
,/,
the/DT
advantage/NN
of/IN
NGS/NN
is/VBZ
not/RB
restricted/JJ
to/TO
these/DT
applications/NNS
./.
====================
It/PRP
serves/VBZ
a/DT
platform/NN
for/IN
the/DT
identification/NN
of/IN
novel/JJ
RNAs/NNS
or/CC
DNAs/NNS
./.
====================
For/IN
example/NN
,/,
the/DT
long/JJ
noncoding/JJ
RNAs/NNS
(/(
lncRNAs/NNS
)/)
that/WDT
are/VBP
transcribed/VBN
from/IN
intergenic/JJ
and/CC
intronic/JJ
regions/NNS
have/VBP
been/VBN
identified/VBN
in/IN
prostate/NN
cancers/NNS
i.e./FW
,/,
prostate/NN
cancer-associated/JJ
ncRNA/JJ
transcripts/NNS
(/(
PCATs/NNS
)/)
[/(
23/CD
]/)
./.
====================
A/DT
novel/JJ
class/NN
of/IN
DNA/NN
i.e./FW
,/,
extrachromosomal/JJ
microDNA/JJ
,/,
has/VBZ
been/VBN
recently/RB
found/VBN
by/IN
NGS/NN
technology/NN
,/,
which/WDT
is/VBZ
derived/VBN
from/IN
unique/JJ
non-repetitive/JJ
sequence/NN
enriched/VBN
in/IN
5'-UTR/NN
,/,
exons/NNS
,/,
and/CC
CpG/NN
islands/NNS
[/(
24/CD
]/)
./.
====================
The/DT
role/NN
of/IN
microDNA/NN
in/IN
cancer/NN
will/MD
be/VB
the/DT
next/JJ
question/NN
./.
====================
Challenges/NNS
in/IN
cancer/NN
genomics/NNS
====================
The/DT
primary/JJ
study/NN
goals/NNS
of/IN
cancer/NN
genomics/NNS
are/VBP
not/RB
simple/JJ
,/,
which/WDT
include/VBP
the/DT
studies/NNS
to/TO
get/VB
either/CC
clinical/JJ
or/CC
mechanistic/JJ
insights/NNS
from/IN
the/DT
cancer/NN
genome/NN
./.
====================
To/TO
clarify/VB
the/DT
complicated/VBN
study/NN
designs/VBZ
and/CC
strategies/NNS
of/IN
cancer/NN
genomics/NNS
,/,
we/PRP
have/VBP
categorized/VBN
the/DT
gene/NN
signatures/NNS
obtained/VBN
from/IN
cancer/NN
genome/NN
data/NNS
into/IN
four/CD
classes/NNS
prediction/NN
,/,
phenotype/NN
,/,
function/NN
,/,
and/CC
molecular/JJ
targets/NNS
based/VBN
on/IN
the/DT
study/NN
goals/NNS
[/(
25/CD
]/)
./.
====================
The/DT
majority/NN
of/IN
the/DT
previous/JJ
studies/NNS
have/VBP
suggested/VBN
the/DT
translational/JJ
or/CC
clinical/JJ
utility/NN
of/IN
the/DT
genomics/NNS
data/NNS
by/IN
addressing/VBG
the/DT
candidate/NN
biomarkers/NNS
or/CC
the/DT
prediction/NN
signatures/NNS
for/IN
predicting/VBG
patients/NNS
clinical/JJ
outcomes/NNS
,/,
such/JJ
as/IN
recurrence/RB
,/,
survival/NN
,/,
metastasis/NN
,/,
or/CC
response/NN
to/TO
therapies/NNS
./.
====================
Notwithstanding/VBG
the/DT
overwhelming/JJ
identification/NN
of/IN
candidate/NN
biomarkers/NNS
from/IN
the/DT
cancer/NN
genome/NN
,/,
only/RB
a/DT
handful/JJ
of/IN
candidate/NN
biomarkers/NNS
that/IN
have/VBP
been/VBN
discovered/VBN
from/IN
genomic/JJ
analyses/NNS
can/MD
succeed/JJ
in/IN
the/DT
validation/NN
of/IN
the/DT
clinical/JJ
utility/NN
[/(
18/CD
]/)
./.
====================
There/EX
are/VBP
several/JJ
challenges/NNS
in/IN
cancer/NN
genomics/NNS
that/DT
preclude/VBP
clinical/JJ
utility/NN
./.
====================
One/CD
of/IN
them/PRP
would/MD
be/VB
data/NNS
reproducibility/NN
./.
====================
They/PRP
might/MD
be/VB
due/JJ
in/IN
part/NN
to/TO
the/DT
experimental/JJ
biases/NNS
as/IN
well/RB
as/IN
sample/JJ
cohort/NN
issues/NNS
./.
====================
The/DT
use/NN
of/IN
different/JJ
platforms/NNS
measuring/VBG
gene/NN
expressions/NNS
and/CC
different/JJ
data/NNS
processing/NN
methods/NNS
could/MD
produce/VB
biased/VBN
observation/NN
in/IN
each/DT
study/NN
./.
====================
Increasing/VBG
sample/NN
size/NN
will/MD
be/VB
one/CD
of/IN
the/DT
solutions/NNS
to/TO
find/VB
proper/JJ
biomarkers/NNS
,/,
overcoming/VBG
the/DT
reproducibility/NN
problem/NN
./.
====================
Undoubtedly/RB
,/,
large-scale/JJ
sample/NN
collection/NN
provides/VBZ
increased/VBD
statistical/JJ
power/NN
./.
====================
However/RB
,/,
previous/JJ
studies/NNS
,/,
even/RB
with/IN
large/JJ
sample/JJ
sizes/NNS
,/,
have/VBP
often/RB
failed/VBD
to/TO
reproduce/VB
their/PRP$
findings/NNS
in/IN
independent/JJ
studies/NNS
[/(
26/CD
]/)
./.
====================
This/DT
might/MD
be/VB
due/JJ
mostly/RB
to/TO
the/DT
use/NN
of/IN
different/JJ
protocols/NNS
and/CC
analysis/NN
methods/NNS
./.
====================
Moreover/RB
,/,
biased/VBD
sample/NN
collection/NN
may/MD
also/RB
affect/VB
the/DT
performance/NN
of/IN
prognostic/JJ
biomarkers/NNS
,/,
leading/VBG
to/TO
subsequent/JJ
failure/NN
to/TO
validate/VB
the/DT
biomarker/NN
in/IN
another/DT
patient/NN
population/NN
[/(
27/CD
]/)
./.
====================
For/IN
example/NN
,/,
diagnostic/JJ
biomarkers/NNS
must/MD
be/VB
discovered/VBN
in/IN
early-stage/JJ
tumors/NNS
;/:
however/RB
,/,
the/DT
sample/JJ
collection/NN
of/IN
early/JJ
tumors/NNS
with/IN
enough/JJ
of/IN
a/DT
sample/JJ
size/NN
might/MD
be/VB
difficult/JJ
in/IN
the/DT
clinical/JJ
setting/VBG
[/(
18/CD
,/,
28/CD
]/)
./.
====================
In/IN
addition/NN
,/,
the/DT
cost-effectiveness/NN
of/IN
the/DT
sample/NN
size/NN
enrolled/JJ
in/IN
a/DT
study/NN
should/MD
be/VB
considered/VBN
./.
====================
Simply/RB
increasing/VBG
the/DT
sample/NN
size/NN
might/MD
not/RB
be/VB
the/DT
best/JJS
solution/NN
./.
====================
The/DT
sample/JJ
sources/NNS
and/CC
qualities/NNS
are/VBP
also/RB
important/JJ
factors/NNS
to/TO
be/VB
considered/VBN
in/IN
the/DT
study/NN
design/NN
./.
====================
For/IN
example/NN
,/,
circulating/VBG
DNAs/NNS
or/CC
microRNAs/NNS
in/IN
the/DT
plasma/NN
or/CC
urine/NN
can/MD
be/VB
used/VBN
to/TO
develop/VB
``/CD
noninvasive/JJ
''/CD
biomarkers/NNS
in/IN
cancer/NN
patients/NNS
,/,
which/WDT
might/MD
bring/VBG
the/DT
technology/NN
much/RB
closer/JJR
to/TO
the/DT
clinic/JJ
[/(
29/CD
,/,
30/CD
]/)
./.
====================
Attempts/NNS
to/TO
use/VB
formalin-fixed/JJ
paraffin-embedded/JJ
(/(
FFPE/NN
)/)
tissues/NNS
might/MD
also/RB
be/VB
more/RBR
applicable/JJ
to/TO
the/DT
clinic/JJ
[/(
31/CD
]/)
,/,
although/IN
the/DT
quality/NN
and/CC
the/DT
quantity/NN
of/IN
the/DT
DNAs/NNS
or/CC
RNA/NN
extracts/NNS
from/IN
FFPE/NN
or/CC
plasma/NN
are/VBP
still/RB
problematic/JJ
for/IN
genomics/NNS
studies/NNS
requesting/VBG
further/RBR
elaboration/NN
./.
====================
Dissecting/VBG
the/DT
tumor/NN
heterogeneity/NN
====================
The/DT
data/NNS
complexity/NN
comes/VBZ
not/RB
only/RB
from/IN
the/DT
heterogeneous/JJ
or/CC
biased/VBN
sample/NN
composition/NN
,/,
but/CC
also/RB
from/IN
the/DT
innate/JJ
complexity/NN
of/IN
tumor/NN
biology/NN
./.
====================
Previously/RB
,/,
mounting/VBG
evidence/NN
has/VBZ
shown/VBN
the/DT
enormous/JJ
heterogeneity/NN
of/IN
tumors/NNS
at/IN
the/DT
molecular/JJ
level/NN
./.
====================
The/DT
tumor/NN
heterogeneity/NN
can/MD
be/VB
explained/VBN
by/IN
two/CD
hypothetical/JJ
models/NNS
./.
====================
One/CD
is/VBZ
the/DT
clonal/JJ
segregation/NN
model/NN
with/IN
a/DT
multi-step/JJ
process/NN
,/,
and/CC
the/DT
other/JJ
is/VBZ
the/DT
cancer/NN
stem/NN
cell/NN
theory/JJ
./.
====================
The/DT
cancer/NN
stem/NN
cell/NN
model/NN
describes/VBZ
the/DT
heterogeneous/JJ
cellular/JJ
origin/NN
of/IN
cancers/NNS
from/IN
primitive/JJ
progenitor/NN
cells/NNS
to/TO
mature/JJ
differentiated/VBN
cells/NNS
,/,
which/WDT
may/MD
contribute/VB
to/TO
tumor/NN
heterogeneity/NN
./.
====================
In/IN
this/DT
context/NN
,/,
genomic/JJ
profiling/VBG
studies/NNS
could/MD
define/VB
the/DT
cancer/NN
subpopulation/NN
harboring/VBG
stem-like/JJ
traits/VBZ
in/IN
various/JJ
cancer/NN
types/NNS
,/,
supporting/VBG
the/DT
cancer/NN
stem/NN
cell/NN
theory/JJ
[/(
32/CD
,/,
33/CD
]/)
./.
====================
Similarly/RB
,/,
we/PRP
also/RB
defined/VBN
the/DT
bilineal/JJ
trait/VBP
in/IN
a/DT
subpopulation/NN
of/IN
hepatocellular/JJ
carcinoma/NN
(/(
HCC/NN
)/)
by/IN
comparing/VBG
the/DT
gene/NN
expression/NN
profiles/NNS
of/IN
HCC/NN
and/CC
cholangiocarcinoma/NN
(/(
CC/NN
)/)
[/(
34/CD
]/)
./.
====================
This/DT
result/NN
showed/VBD
the/DT
continuous/JJ
liver/NN
cancer/NN
spectrum/NN
between/IN
HCC/NN
and/CC
CC/NN
,/,
suggesting/VBG
that/IN
stem-like/JJ
or/CC
de-differentiation/NN
traits/VBZ
may/MD
give/VB
rise/NN
to/TO
the/DT
heterogeneous/JJ
progression/NN
of/IN
HCC/NN
./.
====================
We/PRP
also/RB
suggested/VBD
that/IN
the/DT
dysfunction/NN
of/IN
p53/NN
machinery/NN
is/VBZ
associated/VBN
with/IN
the/DT
acquisition/NN
of/IN
the/DT
stemness/NN
trait/VBP
in/IN
HCC/NN
[/(
35/CD
]/)
./.
====================
Recently/RB
,/,
this/DT
association/NN
could/MD
be/VB
validated/VBN
by/IN
showing/VBG
p53/NN
knockout/NN
mouse/NN
model/NN
can/MD
give/VB
rise/NN
to/TO
bilineal/JJ
liver/NN
cancers/NNS
[/(
36/CD
]/)
./.
====================
In/IN
addition/NN
,/,
various/JJ
host/NN
factors/NNS
may/MD
contribute/VB
to/TO
tumor/NN
heterogeneity/NN
./.
====================
Interactions/NNS
of/IN
the/DT
tumor/NN
cells/NNS
with/IN
host/NN
eco-system/NN
,/,
such/JJ
as/IN
innate/JJ
immune/JJ
systems/NNS
,/,
or/CC
the/DT
reactions/NNS
of/IN
surrounding/VBG
microenvironment/NN
against/IN
the/DT
tumor/NN
may/MD
affect/VB
the/DT
tumor/NN
behaviors/NNS
[/(
37/CD
]/)
./.
====================
Thus/RB
,/,
the/DT
proper/JJ
detection/NN
of/IN
biomarkers/NNS
might/MD
be/VB
difficult/JJ
without/IN
considering/VBG
the/DT
effect/NN
of/IN
host/NN
factors/NNS
./.
====================
Furthermore/RB
,/,
the/DT
intratumoral/JJ
heterogeneity/NN
of/IN
cancers/NNS
have/VBP
been/VBN
notified/VBN
in/IN
detail/NN
by/IN
genome-wide/NN
sequencing/NN
of/IN
multi-loci/JJ
from/IN
the/DT
same/JJ
tumor/NN
[/(
38/CD
]/)
./.
====================
The/DT
comparison/NN
of/IN
primary/JJ
and/CC
metastatic/JJ
tumors/NNS
by/IN
single/JJ
cell/NN
sequencing/NN
also/RB
revealed/VBD
the/DT
sequential/JJ
mutation/NN
process/NN
during/IN
cancer/NN
progression/NN
[/(
39/CD
]/)
./.
====================
Similarly/RB
,/,
the/DT
comparison/NN
of/IN
mutations/NNS
from/IN
multiple/JJ
HCC/NN
tumors/NNS
in/IN
the/DT
same/JJ
patient/NN
could/MD
define/VB
the/DT
evolutionary/JJ
lineage/NN
among/IN
tumors/NNS
cells/NNS
[/(
40/CD
]/)
./.
====================
Strikingly/RB
,/,
the/DT
development/NN
of/IN
single-cell/JJ
sequencing/NN
technology/NN
could/MD
provide/VB
a/DT
more/RBR
detailed/JJ
and/CC
systematic/JJ
view/NN
on/IN
intra-tumoral/JJ
heterogeneity/NN
[/(
41/CD
,/,
42/CD
]/)
./.
====================
Of/IN
interest/NN
,/,
such/JJ
attempts/NNS
enabled/VBD
the/DT
construction/NN
of/IN
phylogenic/JJ
trees/NNS
from/IN
mutational/JJ
heterogeneity/NN
,/,
which/WDT
revealed/VBD
evolutionary/RB
tumor/NN
growth/NN
opening/VBG
a/DT
new/JJ
field/NN
of/IN
``/NN
cancer/NN
evolution/NN
''/CD
./.
====================
Returning/VBG
to/TO
biology/NN
for/IN
clinical/JJ
utility/NN
====================
As/IN
discussed/VBN
above/IN
,/,
there/EX
are/VBP
many/JJ
factors/NNS
contributing/VBG
to/TO
tumor/NN
heterogeneity/NN
,/,
which/WDT
may/MD
impede/VB
the/DT
discovery/NN
of/IN
new/JJ
biomarkers/NNS
./.
====================
Thus/RB
,/,
we/PRP
are/VBP
now/RB
urgently/RB
in/IN
need/NN
of/IN
developing/VBG
new/JJ
strategies/NNS
for/IN
biomarker/NN
discovery/NN
from/IN
cancer/NN
genome/NN
data/NNS
./.
====================
Considering/VBG
the/DT
huge/JJ
complexity/NN
of/IN
the/DT
cancer/NN
genome/NN
and/CC
the/DT
limitation/NN
of/IN
current/JJ
technologies/NNS
,/,
it/PRP
would/MD
be/VB
a/DT
reliable/JJ
strategy/NN
to/TO
evaluate/VB
the/DT
functional/JJ
relevance/NN
of/IN
the/DT
candidate/NN
biomarkers/NNS
rather/RB
than/IN
simply/RB
showing/VBG
the/DT
statistical/JJ
significance/NN
of/IN
the/DT
association/NN
by/IN
enrolling/VBG
larger/RBR
samples/NNS
or/CC
applying/VBG
more/RBR
stringent/JJ
statistics/NNS
./.
====================
Although/IN
the/DT
conventional/JJ
strategies/NNS
for/IN
biomarker/NN
discovery/NN
do/VBP
not/RB
require/VB
the/DT
functional/JJ
significance/NN
of/IN
the/DT
candidates/NNS
[/(
43/CD
]/)
,/,
current/JJ
hurdles/NNS
in/IN
cancer/NN
genomics/NNS
request/VBP
a/DT
functional/JJ
validation/NN
step/NN
in/IN
the/DT
pipeline/NN
of/IN
the/DT
biomarker/NN
discovery/NN
./.
====================
Our/PRP$
limited/JJ
understanding/NN
of/IN
the/DT
complexity/NN
of/IN
cancer/NN
biology/NN
is/VBZ
a/DT
significant/JJ
challenge/NN
for/IN
translational/JJ
interpretation/NN
of/IN
the/DT
cancer/NN
genome/NN
./.
====================
Challenges/NNS
of/IN
big/NN
data/NNS
issues/VBZ
and/CC
integromics/NNS
====================
More/RBR
recently/RB
,/,
systematic/JJ
structuring/JJ
and/CC
integration/NN
of/IN
multiple/JJ
and/CC
multi-layered/JJ
omics/NNS
data/NNS
resources/VBZ
,/,
i.e/FW
./.
====================
integromics/NNS
,/,
are/VBP
thought/VBN
of/IN
a/DT
state-of-the-art/NN
strategy/NN
./.
====================
The/DT
recent/JJ
establishment/NN
of/IN
The/DT
Cancer/NN
Genome/NN
Atlas/NNS
(/(
TCGA/NN
)/)
and/CC
the/DT
International/JJ
Cancer/NN
Genome/NN
Consortium/NN
(/(
ICGC/NN
)/)
could/MD
accelerate/VB
and/CC
facilitate/VBP
the/DT
integration/NN
and/CC
sharing/VBG
of/IN
cancer/NN
genome/NN
data/NNS
[/(
44/CD
]/)
./.
====================
Multi-layered/JJ
integromics/NNS
could/MD
define/VB
tumor/NN
heterogeneity/NN
,/,
revealing/VBG
pivotal/JJ
aberrations/NNS
of/IN
genetic/JJ
events/NNS
or/CC
signaling/NN
pathways/NNS
[/(
45/CD
]/)
./.
====================
In/IN
parallel/NN
,/,
genomic/JJ
repositories/NNS
for/IN
drug/NN
activities/NNS
have/VBP
been/VBN
established/VBN
[/(
46-48/CD
]/)
./.
====================
Linking/JJ
the/DT
profiles/NNS
of/IN
drug/NN
sensitivity/NN
to/TO
the/DT
cancer/NN
genome/NN
could/MD
provide/VB
a/DT
powerful/JJ
platform/NN
to/TO
guide/NN
rational/JJ
and/CC
personalized/VBD
cancer/NN
therapeutics/NNS
./.
====================
Now/RB
,/,
as/IN
genomic/JJ
data/NNS
are/VBP
increasing/VBG
and/CC
accumulating/VBG
enormously/RB
,/,
new/JJ
study/NN
designs/VBZ
and/CC
analysis/NN
strategies/NNS
for/IN
integromics/NNS
might/MD
be/VB
required/VBN
,/,
particularly/RB
with/IN
the/DT
context/NN
of/IN
tumor/NN
heterogeneity/NN
and/CC
the/DT
discovery/NN
of/IN
the/DT
functional/JJ
biomarkers/NNS
./.
====================
As/IN
shown/VBN
in/IN
Fig/NN
./.
====================
1/CD
,/,
the/DT
first/JJ
step/NN
in/IN
cancer/NN
integromics/NNS
is/VBZ
the/DT
dissection/NN
of/IN
tumor/NN
heterogeneity/NN
./.
====================
Then/RB
,/,
the/DT
next/JJ
step/NN
will/MD
be/VB
a/DT
recapitulation/NN
of/IN
the/DT
relations/NNS
between/IN
clinical/biological/JJ
phenotypes/NNS
and/CC
molecular/JJ
genotypes/NNS
in/IN
cancer/NN
subpopulations/NNS
,/,
which/WDT
can/MD
address/VB
novel/JJ
functionalities/VBZ
in/IN
particular/JJ
subpopulations/NNS
of/IN
cancers/NNS
./.
====================
We/PRP
suggest/VBP
that/IN
the/DT
discovery/NN
of/IN
reliable/JJ
candidate/NN
functional/JJ
biomarkers/NNS
as/IN
well/RB
as/IN
functional/JJ
genetic/JJ
alterations/NNS
,/,
so-called/JJ
``/CD
driver/RB
events/NNS
''/CD
,/,
can/MD
be/VB
achieved/VBN
through/IN
performing/JJ
this/DT
step-by-step/JJ
evaluation/NN
of/IN
both/DT
clinical/JJ
and/CC
functional/JJ
utilities/NNS
./.
====================
This/DT
hybrid/NN
study/NN
design/NN
would/MD
open/JJ
an/DT
exciting/VBG
era/NNS
for/IN
developing/VBG
new/JJ
``/NN
functional/JJ
biomarkers/NNS
''/CD
and/CC
preventive/therapeutic/JJ
strategies/NNS
with/IN
the/DT
consideration/NN
of/IN
biological/JJ
backgrounds/NNS
of/IN
tumor/NN
heterogeneity/NN
./.
====================
We/PRP
briefly/RB
reviewed/VBD
the/DT
current/JJ
challenges/NNS
and/CC
perspectives/NNS
of/IN
integrative/JJ
cancer/NN
genomics/NNS
,/,
focusing/VBG
particularly/RB
on/IN
the/DT
complexity/NN
of/IN
omics/NNS
data/NNS
and/CC
cancer/NN
biology/NN
./.
====================
Integromic/JJ
approaches/NNS
with/IN
functional/JJ
evaluation/NN
should/MD
be/VB
considered/VBN
even/RB
for/IN
clinical/JJ
as/IN
well/RB
as/IN
mechanistic/JJ
applications/NNS
of/IN
cancer/NN
genome/NN
data/NNS
./.
====================
Necessarily/RB
,/,
the/DT
challenges/NNS
of/IN
big/NN
data/NNS
(/(
particularly/RB
the/DT
NGS/NN
platforms/NNS
)/)
and/CC
integromics/NNS
should/MD
be/VB
considered/VBN
in/IN
the/DT
study/NN
design/NN
./.
====================
A/DT
deep/JJ
understanding/NN
of/IN
both/DT
cancer/NN
biology/NN
and/CC
omics/NNS
data/NNS
characteristics/NNS
is/VBZ
necessarily/RB
required/VBN
for/IN
successful/JJ
cancer/NN
genome/NN
analysis/NN
./.
====================
Moving/VBG
forward/IN
,/,
it/PRP
is/VBZ
clear/JJ
that/IN
progress/VBP
will/MD
come/VB
through/IN
large-scale/JJ
,/,
wide-scope/JJ
,/,
and/CC
multi-disciplinary/JJ
collaborations/NNS
and/CC
sharing/VBG
systems/NNS
,/,
which/WDT
will/MD
accelerate/VB
the/DT
realization/NN
of/IN
translational/JJ
and/CC
personalized/VBD
medicine/NN
in/IN
the/DT
near/JJ
future/JJ
./.
====================
Hybrid/NN
study/NN
design/NN
for/IN
integromics/NNS
approach/NN
./.
====================
